Health.Global (539787) Stock Analysis

Management will pursue value-accretive M&A opportunities aligned with its values and aimed at expanding in new or existing markets. (+1 more commitment)

Management expects North Bangalore to achieve monthly breakeven during FY27 and reach 60%–65% optimal utilization in its third to fourth year of operation. — target: Monthly breakeven in FY27; 60%–65% utilization in the third to fourth year of operation

Management expects existing hospitals, including their expansions, to contribute 75–80% of company growth for the next couple of years; newer centers are expected to contribute the balance. — target: 75–80% of growth from existing hospitals and their expansions; remainder from newer centers (+4 more commitments)

Onboard a new doctor team in Kolkata.

Improve case mix through talent-building and focused marketing across payor types, without setting a quantified mix or market-share target. (+1 more commitment)

Management described a higher contribution from medical oncology, including immunotherapy and CAR-T therapies, particularly in Bengaluru. Its increasing presence was associated with a lower gross margin, partly because of pharmacy costs, but management said the added activity supports EBITDA through better use of hospital capacity. The call gives no specialty revenue share, so the later 39% share cannot be compared quantitatively. (1 expanding)

The December 2025 presentation cited a network of 400+ oncologists. The later baseline reports 450+ revenue-generating oncologists and 88% retention in FY26. The reported oncologist network grew by at least 12.5%, with retention information newly quantified in the later period. (1 expanding)

The December 2025 presentation reported 25 hospitals, 2,515 beds and coverage across 19 cities. The later baseline reports 26 hospitals and more than 3,000 beds, with the same 19-city reach. The hospital count increased 4%; bed capacity expanded materially, while city coverage was stable. (2 expanding)

South accounted for 39% of HCG revenue in FY25, versus 40% in Q1 FY27. The share rose by 1 percentage point (about 2.6% relative), while the later baseline reports year-on-year revenue growth of about 16%. The share comparison is small; the latest reported revenue trajectory is positive. (5 expanding across 4 engines)

HCG reported 38 LINACs, 19 PET-CT scanners and 8 surgical robots in December 2025. The later baseline reports 38 LINACs, 20 PET-CT scanners and 11 robotic systems. LINAC count was stable, PET-CT capacity increased about 5.3%, and robotics expanded about 37.5%, strengthening the technology offering. (4 expanding, 1 stable across 1 engine)

HCG plans further additions at existing hospitals and three greenfield projects: about 75 beds at Cuttack and 50 at Vizag, plus 50 at Suchirayu, 30 at Jaipur, 27 at Nagpur and 23 at Ahmedabad. It also plans around 130 more beds across roughly seven existing hospitals by FY30. The presentation does not give separate commissioning dates for each site, but groups much of this pipeline under FY28–FY30.

Adjusted EBITDA margin increased to 19.4% from 18.2% a year earlier. Management targets 21–22% within two years and says it aims for 24–25% in four to five years, supported by better revenue mix, more complex treatments, maturing hospitals and lower losses at North Bangalore. — Adjusted EBITDA margin: +1.2 percentage points year on year; targets 21–22% in two years and 24–25% in four to five years

HCG’s non-institutional revenue—business outside institutional channels—grew 17% year on year, and its share of revenue rose from 67% to 69%. Management sees this shift toward a better-paying mix as a continuing source of stronger earnings. — Non-institutional revenue share: Non-institutional revenue +17% YoY; share increased by 2 percentage points

HCG targets adding more than 1,000 beds over five years, taking capacity to about 3,500 beds, with 8–10 additional LINACs (radiation-treatment machines). The presentation gives no quarter-by-quarter delivery schedule, so this is a newly stated multi-year expansion plan rather than evidence of an accelerating or decelerating quarterly trend. (5 new trend across 5 signals)

The transcript does not report international-patient revenue or its growth for Q3 FY26. It does give a forward target for medical tourism: increase its share from about 3.5% currently to about 7% within four years. This is a stated growth ambition, not a quarterly revenue series. (1 new trend across 1 signal)

The Dec 2025 plan was to add about 1,000 beds, including roughly 700 through brownfield expansion and 200–400 through greenfield projects, over the coming years. The Aug 2026 baseline identifies a later North Bangalore project of 520 beds planned for FY28–FY29 and says utilization may take until the third or fourth operating year to reach 60%–65%. This later, more specific outlook confirms a prolonged ramp-up risk; no project delay or cost overrun is quantified. (5 intensifying)

The Dec 2025 transcript reported West-cluster revenue of INR 990 crore in FY25, with 17% revenue CAGR since FY20, 10% volume growth, and 6% ARPP growth; it did not state that scheme business was being reduced. The Aug 2026 baseline later reports a deliberate reduction in low-margin government treatments, institutional business down more than 4% year on year, and West-cluster revenue growth of 9%. This later evidence indicates a more visible near-term revenue trade-off. (4 intensifying, 1 emerging)

The Dec 2025 transcript reported FY20–FY25 average realization per patient (ARPP) improvement of 2% in the South cluster, compared with 6% in the West and 9% in the East. Management expected 4%–5% realization improvement annually and planned to add more complex clinical programs and improve the patient mix. The Aug 2026 baseline later reports West-cluster ARPP growth of 2% in Q1 FY27 and identifies fewer high-value therapies and a higher medical-oncology share as constraints. The later evidence shows that realization growth remains modest and mix-sensitive. (4 intensifying, 1 stable)

Expansion plans were concrete in this earlier period: North Bangalore, with more than 120 planned beds, was expected to open by the end of Q4 FY26; Whitefield and other centre expansions were also planned. Management said growth would be phased and maintained guidance of 15%+ rather than the higher growth implied by the capacity pipeline, citing competitive intensity and pricing sensitivity. The Aug 2026 baseline describes a longer utilization ramp and a larger later bed plan, but the document does not provide a comparable utilization or delay figure; the change in risk level cannot be established. (1 insufficient_data, 3 intensifying)

At the earlier FY26 point, HCG reported that the Hebbal facility had opened in May 2026 with capacity of up to 132 beds and was preparing for phased scale-up; around 200 additional beds were also planned over the following 24 months. The later baseline says utilization of 60%–65% is expected only in years three to four and notes 520 beds planned for FY28–FY29. The longer stated utilization runway and larger future build-out leave material delivery and ramp-up risk; no project-level cost or overrun data is provided. (3 intensifying, 2 easing)